Patent details

EP3352735 Title: SUSTAINED RELEASE OLANZAPINE FORMULATIONS

Basic Information

Publication number:
EP3352735
PCT Application Number:
US2016052757
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP167754241
PCT Publication Number:
WO2017053346
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
SUSTAINED RELEASE OLANZAPINE FORMULATIONS
French Title of Invention:
FORMULATIONS D'OLANZAPINE À LIBÉRATION PROLONGÉE
German Title of Invention:
OLANZAPINFORMULIERUNGEN MIT VERZÖGERTER FREISETZUNG
SPC Number:

Dates

Filing date:
21/09/2016
Grant date:
30/08/2023
EP Publication Date:
01/08/2018
PCT Publication Date:
30/03/2017
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
30/08/2023
EP B1 Publication Date:
30/08/2023
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
21/09/2023
Expiration date:
21/09/2036
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
23/08/2023
 
 

Name:
Teva Pharmaceuticals International GmbH
Address:
Schlüsselstrasse 12, 8645 Jona, Switzerland (CH)

Inventor

1

Name:
SMITH, Mark, Alan
Address:
United States (US)

2

Name:
CLAASSEN-PUNT, Carine
Address:
Netherlands (NL)

Priority

Priority Number:
201562221290 P
Priority Date:
21/09/2015
Priority Country:
United States (US)

Classification

IPC classification:
A61K 9/16; A61K 9/00; A61K 47/34; A61K 31/551; A61P 25/18; A61P 25/00;

Publication

European Patent Bulletin

1

Issue number:
202335
Publication date:
30/08/2023
Description:
Grant (B1)

2

Issue number:
202339
Publication date:
27/09/2023
Description:
Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages